Parenteral anticholinergics in dogs with normal and elevated intraocular pressure.
Dogs given parenteral anticholinergic drugs have been thought to be at risk for development or exacerbation of elevated intraocular pressure (IOP). In a randomized, blinded, placebo-controlled study, we evaluated the effect of intramuscular glycopyrrolate (0.01 mg/kg) on pupil diameter and IOP in unanesthetized normal dogs. Treatment with glycopyrrolate did not change pupil diameter or IOP from baseline, nor were there differences between glycopyrrolate and saline-treated (control) dogs. In addition, the authors retrospectively reviewed the medical records of 2,828 dogs undergoing general anesthesia between April 1987 and September 1990 to determine if there was an association between parenteral anticholinergic medication and postanesthetic elevation in IOP. The authors also determined the frequency of bradycardia requiring anticholinergic therapy during anesthesia in dogs with glaucoma. Of the 2,828 cases reviewed, the records of 46 dogs coded for glaucoma were examined in detail. The 46 dogs underwent 62 episodes of anesthesia, with 23 episodes including exposure to an anticholinergic drug. An increase in IOP from preanesthetic to postanesthetic measurement occurred in three dogs. One of these dogs received anticholinergic medication for bradycardia during anesthesia. The postanesthetic elevation in IOP in this dog was probably not drug related. Preanesthetic anticholinergic administration did not affect the incidence of anticholinergic administration for bradycardia during the anesthetic episode. Anticholinergic therapy during anesthesia was more frequent when the preanesthetic medication included an opiate drug. These studies do not indicate an association between parenteral anticholinergic administration and elevations in IOP.
Frischmeyer
K J
KJ
Department of Surgical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison.
Miller
P E
PE
Bellay
Y
Y
Smedes
S L
SL
Brunson
D B
DB
D000768:Anesthesia, General / Q000662:veterinary; D000818:Animals; D004283:Dog Diseases / Q000139:chemically induced / Q000503:physiopathology; D004285:Dogs / Q000502:physiology*; D004311:Double-Blind Method; D005260:Female; D006024:Glycopyrrolate / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D007273:Injections, Intramuscular / Q000662:veterinary; D007429:Intraocular Pressure / Q000187:drug effects*; D008297:Male; D009798:Ocular Hypertension / Q000139:chemically induced / Q000662:veterinary; D011292:Premedication / Q000662:veterinary; D011680:Pupil / Q000187:drug effects; D012189:Retrospective Studies
D006024:Glycopyrrolate